According to reports, pharmaceutical companies will raise the prices of 350 drugs in the United States next year, with an average increase of 4%

According to data from healthcare research firm 3 Axis Advisors, despite pressure from the U.S. government to lower prices, pharmaceutical companies plan to raise the prices of at least 350 brand-name drugs in the U.S., including COVID-19 vaccines, respiratory syncytial virus vaccines, shingles vaccines, and the blockbuster cancer treatment Ibrance.

The research indicates that the number of drug price increases in 2026 has risen compared to the same period last year, when manufacturers announced price hikes for over 250 drugs; this year's median price increase for drugs is approximately 4%, which is consistent with last year